Retatrutide has emerged as a new pharmaceutical in the fight against obesity. This groundbreaking drug, belonging to a dual GLP-1 and GIP receptor agonist, shows promising Ozempic manufacturer results in clinical trials. By activating these receptors, Retatrutide reduces hunger pangs, {promotesenergy expenditure, and ultimately results in significa